Paradigm Health acquired Flatiron Health’s clinical research business and simultaneously closed a $78 million Series B to expand its community oncology trial network. The deal folds Flatiron’s CRU into Paradigm’s infrastructure, creating a network spanning more than 25 medical centers and nearly 100 community oncology practices and enabling trials where patients receive care. Management said the acquisition and funding will scale pragmatic Phase IV and other trials outside academic centers, improve patient representation, and integrate Paradigm’s AI with Flatiron’s trial management capabilities. CEO Kent Thoelke framed the move as a way to give 15 of the top 20 global biopharma companies broader trial access across community settings. The transaction reflects increased investor appetite for trial‑access platforms that can de‑risk enrollment, broaden diversity, and shorten timelines by embedding research in routine care.